A descriptive, retrospective single-centre study of air-leak syndrome in intensive care unit patients with COVID-19.

Publication date: Mar 01, 2025

Acute respiratory failure is the predominant presentation of intensive care unit (ICU) patients with COVID-19, and lung protective strategies are recommended to mitigate additional respiratory complications such as air-leak syndrome. The aim of this study is to investigate the prevalence, type, and timing of air-leak syndrome with regards to associated factors and patient outcome in patients with COVID-19 in ICUs at a large Swedish emergency hospital. This retrospective study included all adult patients admitted to an ICU for COVID-19-related respiratory failure at ScF6dersjukhuset between March 6, 2020, and June 6, 2021. Primary outcomes were proportion of patients diagnosed with air-leak syndrome and its different types of manifestations, and timing of diagnoses in relation to ICU admission and initiation of invasive ventilation. Secondary outcomes included the highest level of respiratory support prior to the diagnosis of air-leak syndrome, patient characteristics and treatment variables associated with air-leak syndrome, and 90-day mortality for patients with air-leak syndrome compared to those without. Out of a total of 669 patients, 81 (12%) were diagnosed with air-leak syndrome. Air-leak syndrome manifested as pneumomediastinum (PMD) (n = 58, 72%), pneumothorax (PTX) (n = 43, 53%), subcutaneous emphysema (SCE) (n = 28, 35%) and pneumatocele (PC) (n = 4, 4. 9%). Air-leak syndrome was diagnosed at a median of 14 days (IQR 6-22) after ICU admission and 12 days (IQR 6-19) following the initiation of invasive ventilation. The highest respiratory support prior to diagnosis was invasive ventilation (IV) in 64 patients (79%), non-invasive ventilation in two patients (2. 5%), and low- or high-flow oxygen in 15 patients (19%). Multiple logistic regression showed that pulmonary disease at baseline (OR 1. 87, 95% CI 1. 07-3. 25), a lower body mass index (OR 0. 95, 95% CI 0. 9-0. 99), admission later compared with earlier in the pandemic (OR 3. 89, 95% CI 2. 14-7. 08), and IV (OR 3. 92, 95% CI 2. 07-7. 44) were associated with an increased risk of air-leak syndrome. Compared with patients not diagnosed with air-leak syndrome, patients with air-leaks had a higher mortality at 90 days after ICU admission, 46% versus 26% (p

Concepts Keywords
June Adult
Mortality Aged
Pneumomediastinum air‐leak syndrome
Swedish barotrauma
COVID-19
COVID‐19
Female
Humans
intensive care
Intensive Care Units
Male
Mediastinal Emphysema
Middle Aged
Pneumothorax
Respiration, Artificial
Respiratory Insufficiency
Retrospective Studies
Sweden

Semantics

Type Source Name
drug DRUGBANK Medical air
disease MESH syndrome
disease MESH COVID-19
disease MESH respiratory failure
disease MESH complications
disease MESH emergency
disease MESH pneumomediastinum
disease MESH pneumothorax
disease MESH subcutaneous emphysema
drug DRUGBANK Oxygen
disease MESH pulmonary disease

Original Article

(Visited 2 times, 1 visits today)